'Flat-fixed dosing' of chemotherapy: A concept whose time has come?

Current Oncology Reports

Volumn 7, Issue 1, 2005, Pages 1-2

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; IRINOTECAN; PACLITAXEL;

BODY SURFACE; BREAST CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; EDITORIAL; HEMATOLOGIC DISEASE; HUMAN; MEDICATION ERROR; NEUTROPENIA; RISK ASSESSMENT;

EID: 14044270802     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0014-0     Document Type: Editorial

References (9)

1. Leape LL, Brennan TA, Laird N, et al.: The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991, 324:377-384.
2. Leape LL: Preventing adverse drug events. Am J Health Syst Pharm 1995, 52:379-382.
3. Anderson BJ, Ellis JF: Common errors of drug administration in infants: causes and avoidance. Paediatr Drugs 1999, 1:93-107.
4. Taxis K, Barber N: Ethnographic study of incidence and severity of intravenous drug errors. BMJ 2003, 326: 84-687.
5. Bordun LA, Butt W: Drug errors in intensive care. J Paediatr Child Health 1992, 28:309-311.
6. Gurney H: How to calculate the dose of chemotherapy. Br J Cancer 2002, 86:1297-1302.
7. Gurney HP, Ackland S, Gebski V, et al.: Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 1998, 16:2299-2304.
8. de Jong FA, Mathijssen RHJ, Xie R, et al.: Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 2004, 10: 068-4071.
9. Miller AA, Rosner GL, Egorin MJ, et al.: Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics/pharmacodynamics in women with solid tumors (CALGB 9763) [abstract]. Proc ASCO 2003, 22:125a.